Entacapone

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 8, 2010, Pages 983-993

  Müller, Thomas ^a,b  

^a St Joseph Hospital Berlin Weissensee   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Entacapone; Levodopa; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; ALPHA TOCOPHEROL; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; DIDANOSINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; IMIPRAMINE; LEVODOPA; SELEGILINE; TOLCAPONE; ANTIPARKINSON AGENT; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENZYME INHIBITOR; NITRILE;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIARRHEA; DOPAMINERGIC SYSTEM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; GASTROINTESTINAL ABSORPTION; HUMAN; LIVER DISEASE; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; REVIEW; RHABDOMYOLYSIS; TABLET FORMULATION; ANIMAL; BIOAVAILABILITY; DRUG COMBINATION; DYSKINESIA, DRUG-INDUCED; HALF LIFE TIME; PATHOPHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; BIOLOGICAL AVAILABILITY; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE INHIBITORS; CATECHOLS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; ENZYME INHIBITORS; HALF-LIFE; HUMANS; LEVODOPA; NITRILES; PARKINSON DISEASE;

EID: 77954851817     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.502167     Document Type: Review

References (72)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5(6):525-535
2. Foley P, Riederer P. Pathogenesis and preclinical course of Parkinson's disease. J Neural Transm Suppl 1999;56:31-74
3. Przuntek H, Muller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 2004;111(2):201-216
4. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498-2508
5. Rascol O. Monoamine oxidase inhibitors-is it time to up the TEMPO? Lancet Neurol 2003;2(3):142-143
6. Muller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother 2006;7(13):1715-1730
7. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284(15):1931-1938
8. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61(4):561-566
9. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37(1):23-27
10. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;53(5):1012-1019
11. Ceravolo R, Piccini P, Bailey DL, et al. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002;43(3):201-207
12. Gervas JJ, Muradas V, Bazan E, et al. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983;33(3):278-282
13. Guttman M, Leger G, Reches A, et al. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 1993;8(3):298-304
14. Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987;21(6):584-588
15. Mannisto PT. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors. Adv Pharmacol 1998;42:324-328
16. Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994;44(7):1292-1297
17. Hauser RA, Panisset G, Abbruzzese G, et al. Double-blind trial of levodopa/ carbidopa/entacapone versus levodopa/ carbidopa in early Parkinson's disease. Mov Disord 2008;24:39-48
18. Brooks DJ, Agid Y, Eggert K, et al. Treatment of end-of-dose wearing-off in Parkinson's disease: stalevo (levodopa/ carbidopa/entacapone) and levodopa/ DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 2005;53(4):197-202
19. Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004;61(10):1563-1568
20. Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105(4):245-255
21. Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology 2004;62(1 Suppl 1):S39-46
22. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63(4):421-428
23. Benabou R, Waters C. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease. Expert Opin Drug Saf 2003;2(3):263-267
24. Blandini F, Nappi G, Fancellu R, et al. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. J Neural Transm 2003;110(8):911-922
25. Muller T, Woitalla D, Schulz D, et al. Tolcapone increases maximum concentration of levodopa. J Neural Transm 2000;107(1):113-119
26. Russ H, Muller T, Woitalla D, et al. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol 1999;360(6):719-720 (Pubitemid 30012474)
27. Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord 2007;22(1):14-19
28. Factor SA, Molho ES, Feustel PJ, et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 2001;24(5):295-299
29. Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004;62(1 Suppl 1):S72-81
30. Muller T, Erdmann C, Muhlack S, et al. Inhibition of catechol-O- methyltransferase contributes to more stable levodopa plasma levels. Mov Disord 2006;21(3):332-336
31. Nutt JG. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 2000;55(11 Suppl 4):S33-7
32. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000;55(11 Suppl 4):S72-7
33. Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 1996;30(6):463-481
34. Mouradian MM, Heuser IJ, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25(5):523-526
35. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(4 Suppl 1):S2-9
36. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999;246(12):1127-1133
37. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16(3):448-458
38. Cubo E, Gracies JM, Benabou R, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol 2001;58(9):1379-1382
39. Kostic VS, Marinkovic J, Svetel M, et al. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 2002;9(1):9-14
40. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005;20(3):342-344
41. Meiler B, Andrich J, Muller T. Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. Mov Disord 2008;23(1):145-146
42. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006;45(2):109-136
43. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342(20):1484-1491
44. Rascol O. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. J Neurol 2000;247(Suppl 2):II51-II57
45. Muller T, Erdmann C, Muhlack S, et al. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm 2006;113(10):1441-1448
46. Stocchi F, Kieburtz K, Rascol O, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson's disease: the Stride-PD Study. Ann Neurol 2010; In press
47. Stocchi F, Kakarieka A, Kieburtz K, et al.; on behalf of the STRIDE-PD investigators. The STRIDE-PD (Stalevo Reduction in Dyskinesia Evaluation) Study. Late breaking abstracts: the Movement Disorders Society's 13th International Congress of Parkinson's Disease and Movement Disorders, 7-11 June 2009
48. Muhlack S, Woitalla D, Welnic J, et al. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. Neurosci Lett 2004;363(3):284-287
49. Murata M, Mizusawa H, Yamanouchi H, Kanazawa I. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J Neural Transm 1996;103(10):1177-1185
50. Woitalla D, Goetze O, Kim JI, et al. Levodopa availability improves with progression of Parkinson's disease. J Neurol 2006;253(9):1221-1226
51. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41(4):261-309
52. Muller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 2006;29(2):61-67
53. Contin M, Riva R, Martinelli P, et al. Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease. Neurology 1996;46(4):1055-1058
54. Fabbrini G, Juncos J, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21(4):370-376 (Pubitemid 17053274)
55. Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology 1987;37(6):940-944
56. Muller T, Woitalla D, Saft C, Kuhn W. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 2000;6(3):171-173
57. Crevoisier C, Zerr P, Calvi-Gries F, Nilsen T. Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. Eur J Pharm Biopharm 2003;55(1):71-76
58. Djaldetti R, Ziv I, Melamed E. Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Isr J Med Sci 1996;32(12):1224-1227
59. Goetze O, Wieczorek J, Mueller T, et al. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett 2005;375(3):170-173
60. Goetze O, Nikodem AB, Wiezcorek J, et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 2006;18(5):369-375
61. Minea D, Varga I, Falup-Pecurariu C, et al. Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease. Clin Neuropharmacol 2001;24(4):235-238
62. Fuente-Fernandez R, Ruth TJ, Sossi V, et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293(5532):1164-1166
63. Fuente-Fernandez R, Phillips AG, Zamburlini M, et al. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 2002;136(2):359-363
64. Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008;23(5):700-707
65. Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology 1988;38(3):419-421
66. Muller T, Woitalla D, Goetze O, Erdmann C. Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease. Mov Disord 2008;23(10):1458-1461
67. Muller T, Kolf K, Ander L, et al. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. Clin Neuropharmacol 2008;31(3):134-140
68. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59(6):1233-1250
69. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51(5):1309-1314
70. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42(5):747-755
71. Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003;74(8):1071-1079
72. Hauser RA, Panisset M, Abbruzzese G, et al. Double-blind trial of levodopa/ carbidopa/entacapone versus levodopa/ carbidopa in early Parkinson's disease. Mov Disord 2009;24(4):541-550